WO2011062263A1 - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- WO2011062263A1 WO2011062263A1 PCT/JP2010/070713 JP2010070713W WO2011062263A1 WO 2011062263 A1 WO2011062263 A1 WO 2011062263A1 JP 2010070713 W JP2010070713 W JP 2010070713W WO 2011062263 A1 WO2011062263 A1 WO 2011062263A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- inhibitor
- sequence
- influenza virus
- fragment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 69
- 239000003112 inhibitor Substances 0.000 claims abstract description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 33
- 230000009385 viral infection Effects 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 12
- 230000009471 action Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 87
- 230000001717 pathogenic effect Effects 0.000 claims description 47
- 239000012634 fragment Substances 0.000 claims description 25
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 241001473385 H5N1 subtype Species 0.000 claims description 7
- 102000018265 Virus Receptors Human genes 0.000 claims description 7
- 108010066342 Virus Receptors Proteins 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 230000009545 invasion Effects 0.000 claims description 7
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 239000002911 sialidase inhibitor Substances 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 description 27
- 102000037865 fusion proteins Human genes 0.000 description 27
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 101710154606 Hemagglutinin Proteins 0.000 description 13
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 13
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 13
- 101710176177 Protein A56 Proteins 0.000 description 13
- 239000000185 hemagglutinin Substances 0.000 description 13
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 12
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 12
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 8
- 102000005348 Neuraminidase Human genes 0.000 description 7
- 108010006232 Neuraminidase Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000012758 nuclear staining Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 241001641735 Cygnus cygnus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- -1 olive oil Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940061374 relenza Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a pharmaceutical composition.
- Type A is a zoonotic disease.
- Influenza A virus has many subtypes due to the combination of 16 types of hemagglutinin (HA) and 9 types of neuraminidase (NA) on the membrane surface. According to the antigenicity of HA, it is classified into low pathogenic virus and highly pathogenic virus, but low pathogenic virus infects only locally (respiratory organs and intestinal tract), whereas HA antigenicity is H5. Type and H7 highly pathogenic viruses infect and propagate organs throughout the body and kill the host.
- HA hemagglutinin
- NA neuraminidase
- Influenza virus When influenza virus infects cells, it is necessary for HA to bind to cell surface receptors. Influenza virus binds to the receptor, enters the cell, and grows inside the cell. In this case, the low pathogenic virus is required to be cleaved by a protease secreted locally outside the cell, thereby acquiring the ability to infect cells, so that HA cleavage and infection are coupled.
- a highly pathogenic virus is proliferated in a cell and then released to the outside of the cell, the HA is cleaved to acquire the ability to infect cells. Therefore, the highly pathogenic virus present outside the cells is already infectious, so HA cleavage and infection are not coupled. Therefore, highly pathogenic virus HA is called self-cleaving type (Kawaoka, Y. and Webster, R. G., Proc. Natl Acad. Sci. USA vol.85, p.324-328, 1988) .
- avian influenza virus since the receptor to which influenza virus infects is animal species-specific, avian influenza virus usually does not infect humans. However, it has been pointed out that the avian influenza virus is mutated, the receptor recognition changes, and the risk of infecting humans.
- An object of the present invention is to provide an influenza virus infection inhibitor.
- One embodiment of the present invention is an antibody that recognizes a peptide having an RR sequence, particularly the amino acid sequence RERRRKKR (SEQ ID NO: 1), or a fragment thereof, or an expression vector that expresses at least one of them.
- the antibody or fragment thereof preferably recognizes the RR sequence as an epitope, particularly the amino acid sequence of RERRRKKR (SEQ ID NO: 1).
- the antibody or fragment thereof may be a polyclonal antibody or a monoclonal antibody.
- a further embodiment of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an inhibitor that inhibits the cellular transduction action of an RR sequence, particularly RERRRKKR (SEQ ID NO: 1), a cell of a peptide having an amino acid sequence of RR sequence, particularly RERRRKKR (SEQ ID NO: 1) It is an entry inhibitor that inhibits entry into the inside.
- the inhibitor may be the antibody or a fragment thereof, or an expression vector that expresses any of them.
- the highly pathogenic influenza virus may be a type A H5N1 subtype.
- a further embodiment of the present invention is a highly pathogenic influenza virus infection inhibitor that inhibits infection of cells with a highly pathogenic influenza virus, or a medicament for preventing or treating influenza with a highly pathogenic influenza virus, It contains an inhibitor that inhibits the cell introduction effect of the RR sequence, particularly RERRRKKR (SEQ ID NO: 1).
- the cells preferably do not have a functional influenza virus receptor, and are preferably cells other than those of the respiratory tract and intestinal tract. In the case of cells of the respiratory tract and intestinal tract, the function of the influenza virus receptor is preferred. Is preferably inhibited.
- the inhibitor may be the antibody or a fragment thereof, or an expression vector that expresses any of them.
- the highly pathogenic influenza virus may be a type A H5N1 subtype.
- a further embodiment of the present invention is a method for preventing or treating highly pathogenic influenza viruses, wherein cell transfer of RR sequences, particularly RERRRKKR (SEQ ID NO: 1), into healthy individuals or influenza patients infected with highly pathogenic influenza viruses.
- Administering an inhibitor that inhibits the action may be the antibody or a fragment thereof, or an expression vector that expresses any of them.
- the highly pathogenic influenza virus may be a type A H5N1 subtype.
- it may be administered to the patient while inhibiting the route of infection by the low pathogenic influenza virus, and for example, a neuraminidase inhibitor may be used in combination.
- the neuraminidase inhibitor is preferably selected from the group consisting of oseltamivir, zanamivir, salts thereof, hydrates thereof, and mixtures thereof.
- Example of this invention it is a figure which shows that the peptide which has RR arrangement
- the upper left is a fluorescence signal by GFP
- the upper right is a signal by antibody staining using an anti-GFP antibody
- the lower left is a nuclear staining signal by DAPI
- the lower right is a fluorescence signal by GFP / anti-GFP antibody.
- This is a triple image of a signal by antibody staining and a nuclear staining signal by DAPI.
- the four photos in the left column show the nuclear staining signal with DAPI, the four photos in the right column show the signal with antibody staining using anti-GFP antibody, and the top four photos recognize the peptide with RR sequence.
- the results of an experiment using a GFP-RR fusion protein treated with a polyclonal antibody and a control experiment using a GFP-RR fusion protein treated with rabbit serum before immunization are shown in the lower four photographs.
- A shows the results of a control experiment using a GFP-RR fusion protein treated with pre-immune rabbit serum
- B shows an experiment using a GFP-RR fusion protein treated with a polyclonal antibody that recognizes a peptide having an RR sequence. Results are shown.
- it is a figure which shows that a RR sequence specific antibody has an infection inhibitory effect, when the highly pathogenic influenza virus is infected with respect to the cell which removed the sialic acid of the cell surface by the sialidase.
- A shows experimental results of infection with highly pathogenic influenza virus treated with PBS
- B shows experimental results of treatment with serum containing RR sequence-specific antibody.
- the right figure of B is a photograph of the cell nucleus stained with DAPI.
- One embodiment of the present invention is an inhibitor that inhibits the cell introduction action of RR sequences, particularly RERRRKKR (SEQ ID NO: 1).
- the inhibitor is preferably an antibody that recognizes a peptide having an RR sequence (hereinafter referred to as an RR peptide-recognizing antibody), but is not particularly limited as long as it inhibits the cell introduction action of the RR sequence.
- Aptamer, cyclic peptide Alternatively, a low molecular compound or the like may be used.
- an antibody it is not particularly limited as long as it structurally inhibits the function of the RR sequence, but it is preferable to recognize the RR sequence as an epitope.
- This antibody may be monoclonal, polyclonal, or an artificial antibody such as a human antibody. These antibodies can be produced according to production methods apparent to those skilled in the art.
- the antigen used in that case may be the RR sequence itself, or a hapten or the like may be bound thereto.
- the RR sequence is a basic amino acid sequence that the highly pathogenic influenza virus has at the HA cleavage site, and consists of amino acids of 5 to 8 bases.
- RERRRKKR SEQ ID NO: 1 possessed by type A H5N1 subtype influenza virus and its mutant sequence (SEQ ID NO: 2 to 4), and basic amino acid sequence possessed by type A H7 subtype influenza virus (SEQ ID NO: 5-9) (see Table 1).
- Another embodiment of the present invention may be a fragment of an RR peptide recognition antibody.
- the antibody fragment is not particularly limited as long as it is a part of an antibody and contains an antigen-binding site containing a variable region.
- a Fab fragment, an F (ab ′) 2 fragment, or the like can be used. These fragments can be obtained, for example, by partially digesting a monoclonal antibody with a proteolytic enzyme.
- the proteolytic enzyme may be any as long as it can obtain Fab fragments and F (ab ′) 2 fragments.
- a protease such as pepsin or ficin should be used. Can do.
- Still other embodiments include DNA encoding an RR peptide recognition antibody or fragment thereof, or an expression vector having the DNA and expressing the RR peptide recognition antibody or fragment thereof.
- DNAs and expression vectors can be produced according to production methods apparent to those skilled in the art.
- RR peptide-recognizing antibodies or fragments thereof are prepared by preparing an expression vector using a promoter that functions in Escherichia coli or mammalian cultured cells, etc., introducing it into a host cell, and expressing and purifying the antibody or fragment thereof. May be. At that time, it is preferable to add a signal peptide and secrete it outside the cell.
- RR sequence inhibitory substance that inhibits the cell introduction action of RR sequence, particularly RERRRKKR (SEQ ID NO: 1), preferably a RR peptide recognition antibody or fragment thereof has a portion having this RR sequence by binding to a peptide having the RR sequence. Can inhibit the interaction with the cell membrane and prevent this peptide from entering the cell. Therefore, the RR sequence inhibitor can be used in in vivo and in in vitro as an entry inhibitor that inhibits the entry of a peptide having an RR sequence into a cell.
- An expression vector that can secrete an RR peptide-recognizing antibody or fragment thereof outside the cell can also be used as an entry inhibitor.
- the target cells are not particularly limited, but cells that are not infected with a low pathogenic influenza virus, but are infected with a highly pathogenic influenza virus, for example, preferably do not have a functional influenza virus receptor.
- cells other than those of the respiratory tract and intestinal tract are preferable, but in the case of cells of the respiratory tract and intestinal tract, it is preferable that the function of the influenza virus receptor is inhibited.
- the functional influenza virus receptor is a receptor used to infect a low-pathogenic influenza virus, that is, a sugar chain structure containing sialic acid on the cell surface, and the influenza virus may be infected. It means a possible receptor.
- the method for inhibiting the function is not particularly limited. For example, sialic acid on the cell surface may be removed by sialidase, and a compound that binds to sialic acid competitively with influenza virus may be administered.
- highly pathogenic influenza viruses have an RR sequence at the terminal of the outer shell peptide, and enter the cell using that sequence. Therefore, the RR sequence inhibitor binds to the outer peptide and inhibits highly pathogenic influenza virus from entering the cell.
- the RR sequence inhibitor can be used as a highly pathogenic influenza virus infection inhibitor.
- the highly pathogenic influenza virus is not particularly limited as long as it is systemic infectious, but preferably has an RR sequence at the cleavage site of HA and is already cleaved when proliferating in the cell and released outside the cell. It is preferable that the outer shell peptide has an RR sequence at the terminal. Specific examples include influenza viruses whose HA antigenicity is H5 or H7.
- the RR sequence inhibitor can inhibit the highly pathogenic influenza virus from entering the cells, it can be used as a pharmaceutical composition for diseases caused by the highly pathogenic influenza virus.
- the administration target of the pharmaceutical composition is not particularly limited as long as it is a vertebrate, but is preferably a human, bird, or pig.
- This pharmaceutical composition may be formulated into tablets, powders, granules, powders, capsules, solutions, emulsions, suspensions, etc. by adding a pharmaceutically acceptable carrier as necessary.
- a medicine for preventing or treating influenza can be produced.
- the pharmaceutically acceptable carrier used here can be appropriately selected from conventionally used carriers according to the form of the pharmaceutical to be prepared.
- purified water sterile water
- physiological buffer glycol, glycerol
- injectable organic esters such as olive oil, and the like
- this medicine may contain conventionally used stabilizers, excipients and the like.
- the administration method of the medicine there are no particular limitations on the administration method of the medicine, and it may be appropriately determined according to various preparation forms, patient age, sex, other conditions, severity of disease, etc.
- Parenteral dosage forms such as drops and sprays are preferred.
- it when used as an injection or infusion, it is administered intravenously, intramuscularly, intradermally, subcutaneously, or intraperitoneally, if necessary, mixed with a salt solution, a normal fluid such as glucose or amino acid.
- This medicament may be used alone or in combination with other drugs (for example, other antiviral agents, anti-inflammatory agents, drugs that relieve symptoms, etc.).
- oseltamivir which is an inhibitor thereof, or a salt or hydrate thereof (for example, Tamiflu (Roche) which is a phosphate) It is preferably used in combination with a neuraminidase inhibitor such as zanamivir or a salt or hydrate thereof (for example, Relenza (Glaxo) which is a hydrate).
- a neuraminidase inhibitor such as zanamivir or a salt or hydrate thereof (for example, Relenza (Glaxo) which is a hydrate).
- the RR sequence inhibitor and neuraminidase inhibitor may be administered at the same time, but there is no problem even if they are administered before and after the time as long as one effect is within the period.
- GFP-RR fusion protein The RR sequence was amplified by PCR using H5N1 highly pathogenic avian influenza Vietnam1203 strain DNA and the following primers. forward: ACCATTggggAATgCCCCAAATATgTgAAATC (SEQ ID NO: 10) reverse: CgACAAgCTTgAATTCTTATCTCTTTTTTCTTCTTCTCTC (SEQ ID NO: 11) This sequence and the EGFP gene or EGFP gene alone were incorporated into a protein expression vector pCold-II (Takara). EGFP was amplified with the following primers.
- EGFP primer-F CgAgggATCCgAATTCAgTAAAggAgAAgAACTTTTCAC (SEQ ID NO: 12)
- EGFP primer-R gCATTCCCCAATggTTTTgTATAgTTCATCCATgCCATg (SEQ ID NO: 13)
- pCold-II was cleaved with EcoRI. DNA was integrated by homologous recombination using Takara's kit In-fusion. GFP contained in GFP-RR was prepared as a fusion protein on the N-terminal side of the RR sequence.
- This expression vector was introduced into Escherichia coli Rosseta-Gami (Novagen) for gene introduction and cultured at 15 ° C. for 48 hours. The cultured bacterial solution was lysed with BugBuster (Novagen) and then purified with Ni-Sepharose (GE healthcare).
- the weakly shining signal is a signal of nuclear staining with DAPI.
- the brightly shining signal is that of the GFP-RR fusion protein.
- mice were immunized with a synthetic peptide (sequence: CTGLRNSPQRERRRRKKR (SEQ ID NO: 14)) four times every two weeks. 100 ⁇ g of peptide was injected intraperitoneally or subcutaneously for the first immunization and 100 ⁇ g of the peptide after the second immunization. As an adjuvant, TiterMax Gold (Funakoshi) was used for the first immunization, and 300 ⁇ l each of incomplete Freund's adjuvant was used after the second time. Two weeks after the final immunization, mice were killed and spleens were collected, and monoclonal antibodies were prepared as usual. And the antibody reacting with the said peptide was obtained by screening by ELISA using the said peptide used for immunization.
- a synthetic peptide sequence: CTGLRNSPQRERRRRKKR (SEQ ID NO: 14)
- FIG. 2 shows fluorescence micrographs (2 fields of view) in which staining was observed.
- an antibody against the RR sequence is an inhibitor that inhibits the protein having the RR sequence from entering the cell, and therefore inhibits the cell introduction action of the RR sequence.
- Fab fragments were purified from the purified antibody obtained using Pierce Fab Preparation Kit (Thermo Fisher Scientific) according to the protocol. Specifically, the purified antibody was cleaved using papain, the Fc fragment and undigested IgG were adsorbed to protein A, and the Fab fragment was purified.
- the treated C1C12 cells were fixed with paraformaldehyde and blocked at 37 ° C. for 30 minutes with a solution obtained by adding anti-GFP antibody (rabbit polyclonal, MBL, 500-fold diluted) to skim milk. Subsequently, after treatment with 0.1% TritonX-100 for 30 minutes at room temperature, the mixture was reacted with an anti-GFP antibody (mouse monoclonal, MBL, 500-fold diluted) as a primary antibody for 30 minutes at 37 ° C. as a secondary antibody.
- anti-GFP antibody goat polyclonal, MBL, 500-fold diluted
- FIG. 3A when a GFP-RR fusion protein treated with pre-immune rabbit serum was administered to C1C12 cells (control experiment), GFP expression was observed in the cells, and the fusion protein entered the cells. It was.
- FIG. 3B when the GFP-RR fusion protein treated with the Fab fragment was used, expression of GFP was not observed in the cells, and entry of the fusion protein into the cells was inhibited.
- the signal shining brightly in a spot shape in FIG. 3A is a signal of the GFP-RR fusion protein
- the signals shining weakly in a circle in FIGS. 3A and B are signals of nuclear staining by DAPI.
- neuraminidase (Seikagaku Corporation) isolated from Streptococcus 6646K as sialidase
- the cells were treated for 1 hour at 37 ° C to remove sialic acid on the cell surface.
- a / Whooper Swan / Hokkaido / 2008 (H5N1) highly pathogenic avian influenza virus with MOI 1 was further added to the medium to infect the cells.
- the influenza virus used was pre-incubated in PBS or serum described in (3) for 1 hour at 37 ° C.
- FIG. 4 shows a fluorescence micrograph of the observed staining.
- an antibody against the RR sequence is useful as an influenza virus infection inhibitor because it can inhibit the highly pathogenic influenza virus from infecting cells using the RR sequence.
- an influenza virus infection inhibitor can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本出願は、2009年11月20日付で出願した日本国特許出願2009-26539に基づく優先権を主張するものであり、当該基礎出願を引用することにより、本明細書に含めるものとする。
RRペプチド認識抗体またはそのフラグメントは、大腸菌や哺乳類の培養細胞などで機能するプロモーターを用いて発現ベクターを作製し、宿主細胞内に導入して抗体やそのフラグメントを発現させ、精製することによって作製しても良い。その際、シグナルペプチドを付加し、細胞外に分泌させるのが好ましい。
RR配列はH5N1高病原性トリインフルエンザVietnam1203株DNAを用い、下記プライマーを使ってPCRにより増幅した。
forward: ACCATTggggAATgCCCCAAATATgTgAAATC (配列番号10)
reverse: CgACAAgCTTgAATTCTTATCTCTTTTTTCTTCTTCTCTC (配列番号11)
この配列とEGFP遺伝子もしくはEGFP遺伝子単体をタンパク発現ベクターpCold-II(Takara)に組み込んだ。EGFPは以下のプライマーで増幅した。
EGFP primer-F:CgAgggATCCgAATTCAgTAAAggAgAAgAACTTTTCAC (配列番号12)
EGFP primer-R:gCATTCCCCAATggTTTTgTATAgTTCATCCATgCCATg (配列番号13)
pCold-IIはEcoRIにより切断した。TakaraのキットIn-fusionを用いて、相同性組み換えによってDNAを組み込んだ。GFP-RRに含まれるGFPはRR配列のN末端側に融合タンパクとして作成した。この発現ベクターを遺伝子導入用大腸菌Rosseta-Gami (Novagen)に導入し、15℃で48時間培養した。培養した菌液をBugBuster (Novagen)により溶菌後、Ni-Sepharose (GE healthcare)によって精製した。
10 μgのGFP-RR 融合タンパク質またはRR配列を有さないGFPタンパク質を、BHK細胞(1×105cells/ml)の培地(D-MEMに10%FCSを添加した培地とOPTI-MEMを1:9で混合した培地)に添加し、37℃、5% CO2存在下で、3時間インキュベートした。細胞を、パラホルムアルデヒドで固定し、スキムミルクに抗GFP抗体(ポリクローナル、MBL、500倍希釈)を加えたもので30分間、37℃でブロッキングした。続けて0.1%TritonX-100で30分間、室温で処理した後、1次抗体として抗GFP抗体(モノクローナル、MBL、500倍希釈)と30分間、37℃で反応させ、2次抗体としてCy3結合抗マウスIgG抗体(ポリクローナル、Jackson、500倍希釈)と30分間、37℃で反応させることにより免疫染色し、Cy3の蛍光発光を検出することにより、GFP-RR 融合タンパク質が細胞内に侵入するかどうかを調べた。なお、同時に、GFPの蛍光発光を検出するとともに、核をDAPIで染色し、DAPIの蛍光発光を検出した。
RR配列を有さないGFPタンパク質を用いた場合(図1A)、Cy3およびGFPによる発光が検出されず、このタンパク質が細胞内に侵入しなかった。一方、GFP-RR融合タンパク質を用いた場合(図1B)、細胞内でCy3およびGFPによる発光が検出され、この融合タンパク質が細胞内に侵入していた。なお、図1A下及び図1B下の4つの写真で、円形に弱く光っているシグナルがDAPIによる核染色のシグナルであり、図1B左上、右上、及び右下の3つの写真で、斑点状に明るく光っているシグナルが、GFP-RR融合タンパクのシグナルである。
このように、RR配列を有するタンパク質は、それだけで細胞内に侵入することができる。
ウサギに対し合成ペプチド(配列:CTGLRNSPQRERRRRKKR (配列番号14))を二週間毎に4回にわたって免疫を行った。初回免疫に600μg、二次免疫以降に300μgのペプチドを背部皮下注射した。アジュバンドとして初回免疫にTiterMax Gold(フナコシ)、二回目以降に不完全フロイントアジュバンドを各300μl用いた。最終免疫から二週間後に全採血を行い、血清をポリクローナル抗体として用いた。
マウスに対し合成ペプチド(配列:CTGLRNSPQRERRRRKKR (配列番号14))を二週間毎に4回にわたって免疫を行った。初回免疫に100μg、二次免疫以降にも100μgのペプチドを腹腔内または皮下に注射した。アジュバンドとして初回免疫にTiterMax Gold(フナコシ)、二回目以降に不完全フロイントアジュバンドを各300 μl用いた。最終免疫から二週間後にマウスを殺して脾臓を採取し、通常通りモノクローナル抗体を作製した。そして、免疫に使用した上記ペプチドを用いてELISAでスクリーニングすることにより、上記ペプチドに反応する抗体を得た。
GFP-RR融合タンパク質10μgに、10 μlの免疫前あるいは免疫後のウサギ血清を添加し、常温で、3時間インキュベートした。その後、C1C12細胞(1×105個/ml)の培地(D-MEMに10%FCSを添加した培地とOPTI-MEMを1:9で混合した培地)に添加し、37℃、5%CO2存在下で、3時間インキュベートした。
細胞を、パラホルムアルデヒドで固定し、スキムミルクに抗GFP抗体(ポリクローナル、MBL、500倍希釈)を加えた溶液で、30分間、37℃でブロッキングした。続けて0.1%TritonX-100で、30分間、室温で処理した後、1次抗体として抗GFP抗体(モノクローナル、MBL、500倍希釈)と30分間、37℃で反応させ、2次抗体としてCy3結合抗マウスIgG抗体(ポリクローナル、Jackson、500倍希釈)と30分間、37℃で反応させることにより免疫染色し、Cy3の蛍光発光を検出することにより、GFP-RR融合タンパク質が細胞内に侵入するかどうかを、調べた。なお、同時に、核をDAPIで染色した。図2に、染色を観察した蛍光顕微鏡写真(各2視野)を示す。
免疫前のウサギ血清を用いたところ、細胞内でGFPの発現が観察され、融合タンパク質が細胞内に侵入していた(図2下図)。一方、免疫後の抗体を含むウサギ血清を用いたところ、細胞内でGFPの発現が観察されず、融合タンパク質の細胞内への侵入が阻害されていた(図2上図)。なお、図2左カラムの4つの写真で、円形に弱く光っているシグナルがDAPIによる核染色のシグナルであり、図2右下の2つの写真で、斑点状に明るく光っているシグナルが、GFP-RR融合タンパクのシグナルである。
(6)Fabフラグメントによる侵入の阻害
1)Fabフラグメントの作製
まず、免疫後の抗体を含むウサギ血清から、プロテインGを用いてIgG抗体の精製を行った。具体的には、2mlの血清に18mlのTris-HClバッファー(pH=8.0)を加え、15000rpmで10分間遠心分離を行い、Protein G Sepharose 4 Fast Flow (GE Healthcare社)と混合した。混合物をオープンカラムに充填し、10mlのPBS/0.1Tween20、20mlのTris-HClバッファー(pH 8.0)、10mlのPBSで順に洗浄を行った後、1mlの100mM Glycin-HCl (pH=3.0)により溶出し、1mlの1M Tris-HCl (pH=9.0)を加えて中和した。
GFP-RR融合タンパク質10μl(10μg)に、10μlのFabフラグメントを添加し、常温で、3時間インキュベートした。一方、C1C12細胞(1×105個/ml)を準備し、1mlを直径3.5cmの培養皿に播種し、その培地(D-MEMに10%FCSを添加した培地とOPTI-MEMを1:9で混合した培地)に、Fabフラグメントで処理したGFP-RR融合タンパク質を全量(10μg)添加して、37℃、5%CO2存在下で3時間インキュベートした。
このように、RR配列に対する抗体のFabフラグメントでも、RR配列を有するタンパク質が細胞内に入るのを阻害することができるので、RR配列の細胞導入作用を阻害する阻害物質として用いることができる。
ここでは、ノイラミニダーゼ阻害剤投与のモデル系として、シアリダーゼによって細胞表面のシアル酸を除去した細胞に対し、高病原性インフルエンザウイルスを感染させ、RR配列特異的抗体によって、その感染阻害効果を検証した。
Claims (17)
- RR配列を有するペプチドを認識する抗体またはそのフラグメント。
- エピトープとしてRR配列のアミノ酸配列を認識することを特徴とする、請求項1に記載の抗体またはそのフラグメント。
- RR配列が、RERRRKKR(配列番号1)である、請求項1または2に記載の抗体またはそのフラグメント。
- 前記抗体がポリクローナル抗体またはモノクローナル抗体であることを特徴とする、請求項1~3のいずれかに記載の抗体またはそのフラグメント。
- 請求項1~4のいずれかに記載の抗体またはそのフラグメントをコードするDNA。
- 請求項5に記載のDNAを含み、請求項1~4のいずれかに記載の抗体またはそのフラグメントを発現することができる発現ベクター。
- RR配列の細胞導入作用を阻害する阻害物質を含有する医薬組成物。
- 前記阻害物質が、請求項1~4のいずれかに記載の抗体またはそのフラグメント、または請求項6に記載の発現ベクターであることを特徴とする、請求項7に記載の医薬組成物。
- 請求項7に記載の医薬組成物を含有するインフルエンザ予防または治療のための医薬。
- ノイラミニダーゼ阻害剤と併用されることを特徴とする、請求項9に記載のインフルエンザ予防または治療のための医薬。
- RR配列を有するペプチドの細胞内への侵入を阻害する侵入阻害剤であって、
当該RR配列の細胞導入作用を阻害する阻害物質を含有する侵入阻害剤。 - 前記阻害物質が、請求項1~4のいずれかに記載の抗体またはそのフラグメント、または請求項6に記載の発現ベクターであることを特徴とする、請求項11に記載の侵入阻害剤。
- RR配列を有する高病原性インフルエンザウイルスの細胞内への感染を阻害する高病原性インフルエンザウイルス感染阻害剤であって、
当該RR配列の細胞導入作用を阻害する阻害物質を含有する高病原性インフルエンザウイルス感染阻害剤。 - 前記細胞が、機能的なインフルエンザウイルス受容体を有さないことを特徴とする、請求項13に記載の高病原性インフルエンザウイルス感染阻害剤。
- 前記細胞が、呼吸器や腸管以外の細胞であるか、または、呼吸器や腸管の細胞である場合、インフルエンザウイルス受容体の機能が阻害されていることを特徴とする、請求項14に記載の高病原性インフルエンザウイルス感染阻害剤。
- 前記阻害物質が、請求項1~4のいずれかに記載の抗体またはそのフラグメント、または請求項6に記載の発現ベクターを含有することを特徴とする、請求項13~15のいずれかに記載の高病原性インフルエンザウイルス感染阻害剤。
- 前記高病原性インフルエンザウイルスが、A型H5N1亜型であることを特徴とする請求項13~15のいずれかに記載のインフルエンザウイルス感染阻害剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2785376A CA2785376A1 (en) | 2009-11-20 | 2010-11-19 | Pharmaceutical composition |
US13/510,179 US20130129738A1 (en) | 2009-11-20 | 2010-11-19 | Pharmaceutical composition |
SG2012049888A SG182386A1 (en) | 2009-11-20 | 2010-11-19 | Pharmaceutical composition |
EP10831655.5A EP2502995A4 (en) | 2009-11-20 | 2010-11-19 | PHARMACEUTICAL COMPOSITION |
AU2010320091A AU2010320091A1 (en) | 2009-11-20 | 2010-11-19 | Pharmaceutical composition |
JP2011541965A JPWO2011062263A1 (ja) | 2009-11-20 | 2010-11-19 | 医薬組成物 |
CN2010800615538A CN102782129A (zh) | 2009-11-20 | 2010-11-19 | 药物组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009265390 | 2009-11-20 | ||
JP2009-265390 | 2009-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011062263A1 true WO2011062263A1 (ja) | 2011-05-26 |
Family
ID=44059735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/070713 WO2011062263A1 (ja) | 2009-11-20 | 2010-11-19 | 医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20130129738A1 (ja) |
EP (1) | EP2502995A4 (ja) |
JP (1) | JPWO2011062263A1 (ja) |
CN (1) | CN102782129A (ja) |
AU (1) | AU2010320091A1 (ja) |
CA (1) | CA2785376A1 (ja) |
SG (1) | SG182386A1 (ja) |
WO (1) | WO2011062263A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017037014A (ja) * | 2015-08-11 | 2017-02-16 | 池田食研株式会社 | 結合剤 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008040098A1 (en) * | 2006-10-04 | 2008-04-10 | Medvet Science Pty Ltd | Immunogenic polypeptides derived from the cleavage loop of precursor hemagglutinin of an influenza virus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007031550A2 (en) * | 2005-09-15 | 2007-03-22 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
EP2478766A3 (en) * | 2007-05-09 | 2012-08-15 | Burnham Institute for Medical Research | Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens |
US8043856B2 (en) * | 2007-06-14 | 2011-10-25 | Wisconsin Alumni Research Foundation | Adenoviral vectors for influenza virus production |
CN101550188B (zh) * | 2008-04-01 | 2012-05-02 | 南方医科大学 | H5亚型禽流感病毒h5n1血凝素单克隆抗体及其核苷酸序列和制备方法 |
KR101425405B1 (ko) * | 2009-07-17 | 2014-08-01 | 한림대학교 산학협력단 | 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물 |
-
2010
- 2010-11-19 EP EP10831655.5A patent/EP2502995A4/en not_active Withdrawn
- 2010-11-19 CA CA2785376A patent/CA2785376A1/en not_active Abandoned
- 2010-11-19 SG SG2012049888A patent/SG182386A1/en unknown
- 2010-11-19 AU AU2010320091A patent/AU2010320091A1/en not_active Abandoned
- 2010-11-19 WO PCT/JP2010/070713 patent/WO2011062263A1/ja active Application Filing
- 2010-11-19 US US13/510,179 patent/US20130129738A1/en not_active Abandoned
- 2010-11-19 CN CN2010800615538A patent/CN102782129A/zh active Pending
- 2010-11-19 JP JP2011541965A patent/JPWO2011062263A1/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008040098A1 (en) * | 2006-10-04 | 2008-04-10 | Medvet Science Pty Ltd | Immunogenic polypeptides derived from the cleavage loop of precursor hemagglutinin of an influenza virus |
Non-Patent Citations (6)
Title |
---|
"Current Protocols in Molecular Biology", JOHN WILEY & SONS LTD. |
"Molecular cloning, a laboratory manual", 2001, COLD SPRING HARBOR PRESS |
COLACINO J.M. ET AL.: "Approaches and strategies for the treatment of influenza virs infections.", ANTIVIR.CHEM.CHEMOTHER., vol. 10, no. 4, 1999, pages 155 - 185 * |
KAWAOKA, Y.; WEBSTER, R. G., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 324 - 328 |
See also references of EP2502995A4 * |
YUKIKO MURAMOTO ET AL.: "H5Nl Tori Influenza Virus no Kobyogensei Hatsugen Mechanism", MEDICAL BIO, vol. 6, no. 6, 1 November 2009 (2009-11-01), pages 39 - 47 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017037014A (ja) * | 2015-08-11 | 2017-02-16 | 池田食研株式会社 | 結合剤 |
Also Published As
Publication number | Publication date |
---|---|
CA2785376A1 (en) | 2011-05-26 |
JPWO2011062263A1 (ja) | 2013-04-11 |
SG182386A1 (en) | 2012-08-30 |
EP2502995A4 (en) | 2013-05-01 |
EP2502995A1 (en) | 2012-09-26 |
CN102782129A (zh) | 2012-11-14 |
AU2010320091A1 (en) | 2012-07-12 |
US20130129738A1 (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI377212B (en) | Human monoclonal antibodies to influenza m2 protein and methods of making and using same | |
US9605053B2 (en) | Influenza virus-neutralizing antibody and screening method therefor | |
JP5607620B2 (ja) | 抗a型インフルエンザウイルス中和抗体およびその使用 | |
JP2020141708A (ja) | 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのmrgprx2/mrgprb2発現細胞ベースのアッセイ | |
KR102366115B1 (ko) | 신규 ha 결합 물질 | |
JP5840623B2 (ja) | 気道のウイルス感染症の治療に用いるev576 | |
US11999777B2 (en) | Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies | |
KR101749316B1 (ko) | H1n1―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물 | |
US20230192813A1 (en) | Antibody that binds specifically to the sars cov 2 spike protein, and methods for its manufacture | |
BRPI0924072B1 (pt) | Anticorpos antivírus do herpes simples, seu método de produção, uso dos mesmos, ácido nucleico, vetor, célula hospedeira, método de produção da referida célula, bem como composição farmacêutica | |
CN107001429A (zh) | 乙型肝炎病毒表面抗原的表位及与其特异性结合以中和乙型肝炎病毒的结合分子 | |
US9872895B2 (en) | TLR5 ligands, therapeutic methods, and compositions related thereto | |
JP2018052953A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
WO2011062263A1 (ja) | 医薬組成物 | |
CN116390758A (zh) | 用于治疗冠状病毒感染的C5a抑制剂 | |
JPWO2004091476A1 (ja) | 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物 | |
WO2021197340A1 (zh) | 用于治疗冠状病毒的抗体、融合蛋白及其应用 | |
WO2021222988A1 (en) | Cell entry-modulating agents and uses therefor | |
US11655298B2 (en) | Composition for treating fulminant acute pneumonia including CD69 antagonist | |
JPWO2007049805A1 (ja) | 合成リポペプチドおよびその医薬用途 | |
WO2023060483A1 (zh) | 多肽-rbd免疫偶联物及其用途 | |
WO2023143176A1 (zh) | SARS-CoV-2病毒的广谱抗体及其应用 | |
JP2017160168A (ja) | インフルエンザ治療剤 | |
JP2021534239A (ja) | Rsvの改善された受動的および能動的ワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080061553.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10831655 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011541965 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201002303 Country of ref document: TH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010320091 Country of ref document: AU Ref document number: 5352/CHENP/2012 Country of ref document: IN Ref document number: 2010831655 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2785376 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2010320091 Country of ref document: AU Date of ref document: 20101119 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13510179 Country of ref document: US |